Key facts
- This page summarizes OrbiMed Israel GP Ltd.'s Form 4 filing for Chemomab Therapeutics Ltd. (CMMB).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 05 Jan 2023, 15:49.
OrbiMed Israel GP Ltd. - 03 Jan 2023 Form 4 Insider Report for Chemomab Therapeutics Ltd. (CMMB)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- CMMB
- Reported as of
- 03 Jan 2023
- Net transaction value
- -$1,207,759
- SEC form
- 4
- Accepted by SEC
- 05 Jan 2023, 15:49:08 UTC
- Prior SEC filing
- 25 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- OrbiMed Israel BioFund GP Limited, /s/ Douglas Coon, Chief Compliance Officer
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
OrbiMed Israel GP Ltd. filed Form 4 for Chemomab Therapeutics Ltd. (CMMB) on 05 Jan 2023.
Change
- Previous filing in this sequence was filed on 25 Jun 2021.
- Current net transaction value: -$1,207,759.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CMMB
transaction
American Depository Shares
Sale
- Transaction value
- $889,696
- Shares
- -266,376
- Change %
- -10%
- Price
- $3.34
- Shares after
- 2,311,798
- Date
- 03 Jan 2023
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F4, F5
CMMB
transaction
American Depository Shares
Sale
- Transaction value
- $318,063
- Shares
- -70,524
- Change %
- -3.1%
- Price
- $4.51
- Shares after
- 2,241,274
- Date
- 03 Jan 2023
- Ownership
- See Footnotes
- Footnotes
- F1, F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Each American Depository Share ("ADS") represents 20 Ordinary Shares of the Issuer.
Footnote F2
Represents the weighted average sale price of the ADSs sold, ranging from a low of $2.85 to a high of $3.81 per ADS. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of ADSs sold at each separate price.
Footnote F3
Represents the weighted average sale price of the ADSs sold, ranging from a low of $3.87 to a high of $4.83 per ADS. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of ADSs sold at each separate price.
Footnote F4
These ADSs are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the ADSs held directly by OIP and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP.
Footnote F5
This report is being jointly filed by OrbiMed BioFund and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.